Long‐term efficacy and safety of cannabidiol in patients with treatment‐resistant epilepsies: Four‐year results from the expanded access program
Sign Up to like & getrecommendations! Published in 2022 at "Epilepsia"
DOI: 10.1111/epi.17496
Abstract: Cannabidiol (CBD) expanded access program, initiated in 2014, provided add‐on CBD to patients with treatment‐resistant epilepsies (TREs) at 35 US epilepsy centers. Prior publications reported results through December 2016; herein, we present efficacy and safety… read more here.
Keywords: resistant epilepsies; treatment resistant; expanded access; access program ... See more keywords